Women with advanced breast cancer in England could soon benefit from a newly approved targeted treatment on the NHS. The National Institute for Health and Care Excellence (NICE) has recommended the use of capivasertib, a tablet taken alongside fulvestrant, for patients whose hormone receptor-positive, HER2-negative breast cancer has continued to grow after hormone therapy.

This new combination is the latest in a growing range of personalised cancer treatments available on the NHS. Clinical trials showed that patients taking capivasertib with fulvestrant experienced, on average, an additional four months before their disease worsened, compared to those receiving fulvestrant alone.

Professor Peter Johnson, National Clinical Director for Cancer at NHS England, said the treatment could make a real difference for those whose cancer has progressed despite previous therapies. “Although it won’t be the right option for everyone, extending the time before more aggressive treatments are needed can help maintain quality of life and support our goal to personalise care,” he explained.

The decision offers fresh hope for eligible patients, providing a less invasive option that may delay the need for more intensive treatment. The approval reflects ongoing efforts to expand and tailor cancer care, aiming to give patients both more time and greater choice.